Literature DB >> 533579

Serum morphine concentration after oral administration of diamorphine hydrochloride and morphine sulphate.

G W Aherne, E M Piall, R G Twycross.   

Abstract

1 Venous blood was obtained from patients with far-advanced cancer receiving either diamorphine (diacetylmorphine, heroin) hydrochloride (65 samples) or morphine sulphate (24 samples) regularly by mouth in doses from 2.5 mg to 90 mg every 4 h. 2 Samples were obtained within 30 min of the 09.00 h drug round. 3 Serial samples were also obtained over a 4 h period from three patients receiving diamorphine hydrochloride. 4 Assay of serum 'morphine equivalents' was by radioimmunoassay using an antibody that cross reacts almost equally with diamorphine, 6-0 monoacetylmorphine and morphine. 5 The serum concentration of opiates expressed as 'morphine equivalents' ranged from 11 ng/ml to 1440 ng/ml. 6 A highly significant positive linear correlation exists between the dose administered and the serum concentration (P less than 0.001) with respect to both drugs. 7 There was no difference between the two drugs in relation to the serum concentration achieved per 10 mg of opiate administered. 8 Higher oral doses of both diamorphine and morphine are now being used when indicated rather than, as before, resorting to injections when an oral dose in excess of 40 mg is indicated.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 533579      PMCID: PMC1429907          DOI: 10.1111/j.1365-2125.1979.tb01047.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  2 in total

1.  Morphine metabolism in man.

Authors:  S F Brunk; M Delle
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

2.  Choice of strong analgesic in terminal cancer: diamorphine or morphine?

Authors:  R G Twycross
Journal:  Pain       Date:  1977-04       Impact factor: 6.961

  2 in total
  9 in total

1.  Single-dose and steady-state kinetics of morphine and its metabolites in cancer patients--a comparison of two oral formulations.

Authors:  J Hasselström; N Alexander; C Bringel; J O Svensson; J Säwe
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Teaching terminal care.

Authors:  P M Kaye
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-19

3.  Morphine decreases bacterial phagocytosis by inhibiting actin polymerization through cAMP-, Rac-1-, and p38 MAPK-dependent mechanisms.

Authors:  Jana Ninković; Sabita Roy
Journal:  Am J Pathol       Date:  2012-01-14       Impact factor: 4.307

4.  Steady-state kinetics and analgesic effect of oral morphine in cancer patients.

Authors:  J Säwe; B Dahlström; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

5.  Morphine suppresses tumor angiogenesis through a HIF-1alpha/p38MAPK pathway.

Authors:  Lisa Koodie; Sundaram Ramakrishnan; Sabita Roy
Journal:  Am J Pathol       Date:  2010-07-08       Impact factor: 4.307

Review 6.  Role of the mu-opioid receptor in opioid modulation of immune function.

Authors:  Jana Ninković; Sabita Roy
Journal:  Amino Acids       Date:  2011-12-15       Impact factor: 3.520

Review 7.  High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.

Authors:  J Säwe
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

8.  Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites.

Authors:  F J Rowell; R A Seymour; M D Rawlins
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

9.  Opioid Exacerbation of Gram-positive sepsis, induced by Gut Microbial Modulation, is Rescued by IL-17A Neutralization.

Authors:  Jingjing Meng; Santanu Banerjee; Dan Li; Gregory M Sindberg; Fuyuan Wang; Jing Ma; Sabita Roy
Journal:  Sci Rep       Date:  2015-06-03       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.